PCI Biotech announced that it is extending the preclinical research collaboration with an undisclosed pharma company, initiated in September 2015. The extended evaluation period spans over 6 months, until the end of June 2018, and may be further extended. The pharma company is one of the global leaders in nucleic acid therapeutics. The aim of the extension is to further evaluate the synergistic effects of both parties' technology platforms and to determine whether PCI Biotech's fimaNAc technology has the potential to enhance the therapeutic effect of the partner's nucleic acid therapeutic compounds. The companies will evaluate the data generated in this research collaboration and explore the potential for a further partnership based on this outcome.